Company / Operating Cash Flow
SUTRO BIOPHARMA, INC. Operating Cash Flow History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$191.5M
FY2025
5-year range
-$191.5M / $3.5M
FY2021-FY2025
Trend
-5497.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow changed -5497% YoY in FY2025, a notable deviation from the 7-year average annual change of -868%.
Based on SEC 10-K filings.
-$192M in FY2025.
Declined from -$82M to -$192M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow decreased 5497.0% year-over-year.
- Peak operating cash flow was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score -3.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$191.5M | -5497.0% |
| FY2024 | $3.5M | +104.3% |
| FY2023 | -$81.7M | -20.5% |
| FY2022 | -$67.8M | -4.3% |
| FY2021 | -$65.0M | -612.7% |
| FY2020 | $12.7M | +134.2% |
| FY2019 | -$37.1M | -181.9% |
| FY2018 | -$13.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026